Fennec Q2 revenue $3.3M (+98% QoQ); appoints Adrian Haigh as COO

FENNEC PHARMACEUTICALS INC.

2023-Q2 EPS reported -$0.43 revenue$5,002,000

Net product revenue $3.3M in Q2 2023, up 98% from $1.7M in Q1 2023.
Net loss $5.4M ($0.21/share) vs $5.1M ($0.19/share) year ago.
Adrian Haigh appointed COO, steps down from board; base salary €400K, 200K options.
Cash $15.0M at June 30, 2023; sufficient for at least 12 months.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Adrian Haigh

Chief Operating Officer

FENC · FENNEC PHARMACEUTICALS INC.

Effective: 2023-08-03
Filed: August 7, 2023, 7:59 PM ET

Mr. Haigh had accepted the appointment as Chief Operating Officer.

Departed

Adrian Haigh

Director

FENC · FENNEC PHARMACEUTICALS INC.

Effective: 2023-08-03
Filed: August 7, 2023, 7:59 PM ET

Adrian Haigh had stepped down from the the position of Director of Fennec Pharmaceuticals Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Adrian Haigh was appointed as Chief Operating Officer at FENNEC PHARMACEUTICALS INC..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

Mr. Haigh had accepted the appointment as Chief Operating Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Adrian Haigh departed as Director at FENNEC PHARMACEUTICALS INC..

Action: stepped down
Role: Director

Exact text from the filing

Adrian Haigh had stepped down from the the position of Director of Fennec Pharmaceuticals Inc.

View on SEC.gov

FENNEC PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-088184

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.